It should be presented as a clinician-directed adjunctnot as a replacement for nephrology care, blood-pressure control, diabetes treatment, proteinuria management or removal of nephrotoxic exposures
Safety Profile Comparison (2026 Data) Risk Factor Semaglutide (GLP-1) Bariatric Surgery Invasiveness Non-invasive (Injection) Invasive (Surgery) Common Risks Nausea, Vomiting, Constipation Infection, Bleeding, Blood Clots Serious Risks Pancreatitis, Gastroparesis Dumping Syndrome, Malnutrition Anesthesia Risk None Standard Surgical Risk Reversibility Fully Reversible Generally Permanent 2
GHK-Cu makes the most sense as part of a multi-modal protocol for: Men and women in their 30s-60s with early-to-moderate androgenetic alopecia who want to address multiple mechanisms simultaneously, not just DHT blockade
Give it at least 68 weeks of consistent use
Antioxidants 13 (12), 1567